Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Cubicin Threats Line Up, Cubist Spells Out A Strategy

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm seeks new indications, late-stage assets.

You may also be interested in...



Alnylam Inks Deal With Anti-infective Specialist Cubist To Develop RSV Therapy

Respiratory syncytial virus program brought in $35 million upfront from Cubist and an earlier Japanese deal with Kyowa Hakko.

Alnylam Inks Deal With Anti-infective Specialist Cubist To Develop RSV Therapy

Respiratory syncytial virus program brought in $35 million upfront from Cubist and an earlier Japanese deal with Kyowa Hakko.

Optimer Looks To Partner C. Diff Candidate After Trial Success

OPT-80’s success in the clinic dramatically improves Optimer’s ability to partner the product for a healthy sum.

Related Content

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel